Clinical Trial Update: A Single Dose Study of MK-8266 (MK-8266-001) [Phase 1]

View source ↗

Summary

Phase 1 single-dose study of MK-8266 in hypertension completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• MK-8266

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypertension | Phase 1 | Status: COMPLETED | Results posted: 2019-02-20